Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/62115

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

CABOTEGRAVIR IS NOT ASSOCIATED WITH WEIGHT GAIN IN HUMAN IMMUNODEFICIENCY VIRUS–UNINFECTED INDIVIDUALS IN HPTN 077
Landovitz, Raphael J. et al. | Date Issued: 2020
Author
Landovitz, Raphael J.
Zangeneh, Sahar Z.
Chau, Gordon
Grinsztejn, Beatriz
Eron, Joseph J.
Dawood, Halima
Magnus, Manya
Liu, Albert Y.
Panchia, Ravindre
Hosseinipour, Mina C.
Kofron, Ryan
Margolis, David A.
Rinehart, Alex
Adeyeye, Adeola
Burns, David
McCauley, Marybeth
Cohen, Myron S.
Currier, Judith S.
Affilliation
University of California. David Geffen School of Medicine. Center for AIDS Research and Education & Center for HIV Prevention. Department of Medicine. Division of Infectious Diseases. Los Angeles, USA.
Fred Hutchinson Cancer Research Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Fred Hutchinson Cancer Research Center. Vaccine and Infectious Disease Division. Seattle, Washington, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de HIV. Rio de Janeiro, RJ, Brasil.
University of North Carolina. Division of Infectious Diseases. Chapel Hill, USA.
University of KwaZulu-Natal. Department of Medicine. Pietermaritzburg, Durban, South Africa.
George Washington University. Milken Institute School of Public Health. Department of Epidemiology and Biostatistics. Washington, DC, USA.
San Francisco Department of Public Health. Population Health Division. Bridge HIV. California, USA.
University of the Witwatersrand. Chris Hani Baragwanath Academic Hospital. Perinatal HIV Research Unit. Soweto, South Africa.
University of North Carolina. Chapel Hill School of Medicine. Division of Infectious Diseases. North Carolina, USA.
University of California. David Geffen School of Medicine. Center for AIDS Research and Education & Center for HIV Prevention. Department of Medicine. Division of Infectious Diseases. Los Angeles, USA.
ViiV Healthcare. Research Triangle Park. Durham, North Carolina, USA.
ViiV Healthcare. Research Triangle Park. Durham, North Carolina, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Division of AIDS. Rockville, Maryland, USA.
National Institutes of Health. National Institute of Allergy and Infectious Disease. Division of AIDS. Rockville, Maryland, USA.
Science Facilitation Department. Washington DC, USA.
University of North Carolina. Division of Infectious Diseases. Chapel Hill, USA.
University of California. David Geffen School of Medicine. Center for AIDS Research and Education & Center for HIV Prevention. Department of Medicine. Division of Infectious Diseases. Los Angeles, USA.
Abstract
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
Keywords
CAB
HIV Uninfected
Cabotegravir
Weight Gain
 
Publisher
Oxford
Citation
LANDOVITZ, Raphael J. et al. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. Clinical Infectious Diseases, v. 70, n. 2, p. 319-322, Jan. 2020.
DOI
10.1093/cid/ciz439
ISSN
1058-4838